GO
Loading...

Insurance

More

  • Wyeth: More Heartburn From Copycats? Wednesday, 26 Dec 2007 | 11:41 AM ET

    Shares of drugmaker Wyeth could remain under pressure this day after Christmas. At least two analysts are suggesting that Wyeth could be under assault by another generic drug company.

  • A New Hall of Shame Inductee Friday, 21 Dec 2007 | 7:48 PM ET

    MBIA CEO Gary Dunton "has the touch of a great novelist" when it comes to the company's financial reports, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Did Genentech Back Down or Backpedal? Friday, 21 Dec 2007 | 12:11 PM ET

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • HSBC Eyes China Insurance Partner, Asia Jobs Wednesday, 19 Dec 2007 | 12:10 AM ET

    Top European lender HSBC Holdings, which is building up its global insurance business, may strike a distribution partnership in fast-growing China in 2008, its Asia chief said on Wednesday.

  • Eli Lilly

    Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.

  • Amgen: Is It Down To "The Bone" For Investors? Monday, 17 Dec 2007 | 12:32 PM ET

    Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.

  • Norwich Union Fined $2.54 Billion Monday, 17 Dec 2007 | 6:38 AM ET

    British insurance company Norwich Union was fined 1.26 million pounds (1.76 million euros; $2.54 million) on Monday for a data-protection failure that allowed criminals to cash dozens of policies held by customers.

  • Munich Re to Buy Sterling Life for $352 Million Monday, 17 Dec 2007 | 4:05 AM ET

    Reinsurer Munich Re said Monday it reached a deal to buy U.S. healthcare insurer Sterling Life Insurance for $352 million (242.61 million euros) in cash, giving it more access to older Americans who want to buy health insurance.

  • Aon, one of the world's largest insurance brokers, said on Monday it has agreed to sell two units for about $2.75 billion and will devote the proceeds of the deal to a share buyback.

  • Sell Block: How Much Bad Debt Do They Have? Friday, 14 Dec 2007 | 11:45 AM ET

    If American International Group and Capital One won't show their cards, then investors need to cash in their chips.

  • Pharma's Market with Mike Huckman Wednesday, 12 Dec 2007 | 4:30 PM ET

    Last year one of our producers had the bright idea of assigning each of CNBC's beat reporters a story about seven predictions for their beat for 2007. So, now this year not only do we have to do the 8 for '08 thing for TV, but also for the blog.

  • Dick Clark (Merck CEO) Still Rolling Out Hits For Analysts Wednesday, 12 Dec 2007 | 12:13 PM ET

    The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."

  • Swiss Re Loyal to Troubled Unit, Sees Fast Buyback Tuesday, 11 Dec 2007 | 3:57 AM ET

    Reinsurer Swiss Re said it is committed to the Financial Services unit that was the source of last month's large subprime writedown and said it was likely to speed up its share buyback program.

  • Cevian Capital Takes Stake in Munich Re Friday, 7 Dec 2007 | 8:55 AM ET

    Shares of reinsurer Munich Re rose sharply on Friday after a Swedish investment fund disclosed it acquired nearly 3 percent of the world's second-biggest reinsurer.

  • Big Pharma Events: The Pre-Holiday Crunch Wednesday, 5 Dec 2007 | 10:50 AM ET

    I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.

  • Swiss Life Shrugs off Credit Crisis, Boosts Targets Tuesday, 4 Dec 2007 | 4:13 AM ET

    Insurer Swiss Life raised its targets on Tuesday, aiming to boost earnings per share by at least 12 percent annually, and said the credit crisis will not hit its results, lifting its shares.

  • Merger Monday Returns Despite Credit Concerns Monday, 3 Dec 2007 | 12:10 PM ET

    Mergers and acquisitions were back Monday as numerous high-profile companies announced plans to tie up despite recent tightness in the credit market and uncertainty over the strength of Western economies.

  • MetLife Sees Earnings Below Wall Street Estimates Monday, 3 Dec 2007 | 11:15 AM ET

    MetLife, the largest U.S. life insurer, Monday forecast fourth-quarter and 2008 earnings below analysts' expectations, sending its shares down as much as 3.4 percent.

  • Marsh McLennan Names New Marsh CEO Monday, 3 Dec 2007 | 10:26 AM ET

    Marsh & McLennan said Monday that Daniel Glaser will become chairman and chief executive of Marsh Inc, the insurance brokerage's main operating subsidiary, effective Dec. 10.

Contact Insurance

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More